Calcium pyrophosphate deposition
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
mono- or oligoarticular disease
intra-articular corticosteroids
Preferred treatment and are generally well tolerated.[52]Creamer P. Intra-articular corticosteroid treatment in osteoarthritis. Curr Opin Rheumatol. 1999 Sep;11(5):417-21. http://www.ncbi.nlm.nih.gov/pubmed/10503664?tool=bestpractice.com Although their mechanism of action is not fully elucidated, their potent anti-inflammatory action is likely involved.
The treatment should be given at the time of diagnosis. Before injection, synovial fluid should be removed from the affected joint to minimize dilution of the drug.
Lidocaine is typically used as a local anesthetic.
Dose can be repeated every 3 months.
Primary options
dexamethasone sodium phosphate: large joints: 40-80 mg intra-articularly as a single dose; small joints: 10-20 mg intra-articularly as a single dose
OR
triamcinolone acetonide: large joints: 10-40 mg intra-articularly as a single dose; small joints: 5-10 mg intra-articularly
acetaminophen
Treatment recommended for SOME patients in selected patient group
Simple analgesics, such as acetaminophen, may be used for pain relief.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
nonsteroidal anti-inflammatory drugs (NSAIDs)
NSAIDs are effective but should be used cautiously in older patients.[50]Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011 Apr;70(4):571-5. http://ard.bmj.com/content/70/4/571.long http://www.ncbi.nlm.nih.gov/pubmed/21257614?tool=bestpractice.com
Should be used with preventive measures, such as proton-pump inhibitors, in patients at high risk of gastrointestinal complications.[53]Freedberg DE, Kim LS, Yang YX. The Risks and benefits of ong-term use of proton pump inhibitors: expert review and best practice advice From the American Gastroenterological Association. Gastroenterology. 2017 Mar;152(4):706-15. https://www.gastrojournal.org/article/S0016-5085(17)30091-4/fulltext http://www.ncbi.nlm.nih.gov/pubmed/28257716?tool=bestpractice.com
COX-2 inhibitors may be less likely to cause gastrointestinal bleeding than traditional NSAIDs in patients with a history of gastrointestinal bleeding or comorbidities but have been associated with increased risks of cardiovascular events.[54]García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007 Feb;132(2):498-506. https://www.gastrojournal.org/article/S0016-5085(06)02565-0/fulltext http://www.ncbi.nlm.nih.gov/pubmed/17258728?tool=bestpractice.com [55]Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. https://www.bmj.com/content/342/bmj.c7086 http://www.ncbi.nlm.nih.gov/pubmed/21224324?tool=bestpractice.com
Primary options
sulindac: 200 mg orally twice daily for 7-10 days
OR
naproxen: 500 mg orally twice daily for 10-14 days
OR
diclofenac potassium: 50 mg orally (immediate-release) two to three times daily for 10-14 days
OR
meloxicam: 7.5 to 15 mg orally once daily for 10-14 days
OR
celecoxib: 100-200 mg orally twice daily for 10-14 days
acetaminophen
Treatment recommended for SOME patients in selected patient group
Simple analgesics, such as acetaminophen, may be used for pain relief.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
colchicine
Patients with osteoarthritis-like disease or rheumatoid-like disease (i.e., where there is an inflammatory component to the arthritis) may benefit from low-dose colchicine therapy, if kidney and liver function are normal.[56]Meed SD, Spilberg I. Successful use of colchicine in acute polyarticular pseudogout. J Rheumatol. 1981 Jul-Aug;8(4):689-91. http://www.ncbi.nlm.nih.gov/pubmed/7299772?tool=bestpractice.com Evidence for colchicine use in CPPD is mostly extrapolated from evidence for the treatment of acute gout.[50]Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011 Apr;70(4):571-5. http://ard.bmj.com/content/70/4/571.long http://www.ncbi.nlm.nih.gov/pubmed/21257614?tool=bestpractice.com
Minimum effective dose should be used because of the narrow benefit-to-risk index.[57]Neuss MN, McCallum RM, Brenckman WD, et al. Long-term colchicine administration leading to colchicine toxicity and death. Arthritis Rheum. 1986 Mar;29(3):448-9. http://www.ncbi.nlm.nih.gov/pubmed/3964322?tool=bestpractice.com
May be safer than nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with a history of gastrointestinal bleeding or comorbidities.
Colchicine may be given daily or every 3-4 days depending on the frequency of attacks.
Primary options
colchicine: 0.6 mg orally once or twice daily, maximum 1.8 mg/day
acetaminophen
Treatment recommended for SOME patients in selected patient group
Simple analgesics, such as acetaminophen, may be used for pain relief.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
systemic corticosteroids
Reserved for when intra-articular corticosteroid injections have failed or are not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated.
Dosing regimens remain unstudied but there is little evidence that doses >20 mg/day of prednisone are warranted, and lower doses may also be effective.[58]Roane DW, Harris MD, Carpenter MT, et al. Prospective use of intramuscular triamcinolone acetonide in pseudogout. J Rheumatol. 1997 Jun;24(6):1168-70. http://www.ncbi.nlm.nih.gov/pubmed/9195527?tool=bestpractice.com
Long-term corticosteroid use can cause a variety of adverse effects. To minimize the osteoporosis that can develop, these drugs should be given with calcium and vitamin D supplements, and bone densities should be followed yearly.
Other adverse effects such as cataracts, weight gain, and type 2 diabetes mellitus are less controllable. Minimum doses should be sought and risk-to-benefit ratios weighed carefully for these drugs.
One randomized controlled trial conducted between 2018 and 2022 found that, when compared with colchicine, prednisone showed equivalent short-term efficacy for the treatment of acute CPP crystal arthritis in hospitalized patients.[59]Tristan P, Pierre R, Sébastien O, et al. Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial. The Lancet Rheumatology. 2023 Sep;5(9):e523-31. https://www.sciencedirect.com/science/article/abs/pii/S2665991323001650
Primary options
prednisone: 10-20 mg orally once daily, decrease by 5-10 mg/day every 3 days until discontinuation
acetaminophen
Treatment recommended for SOME patients in selected patient group
Simple analgesics, such as acetaminophen, may be used for pain relief.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
combination of analgesics/joint aspiration/splinting
A combination of analgesics, joint aspiration, splinting, and observation may be the safest option for some patients.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
OR
tramadol: 50-100 mg orally (immediate-release) every 4-6 hours when required, maximum 400 mg/day
OR
codeine sulfate: 15-60 mg orally every 4-6 hours when required, maximum 360 mg/day
OR
oxycodone: 5-10 mg orally (immediate-release) every 4-6 hours when required; 10 mg orally (controlled-release) twice daily when required
polyarticular disease
nonsteroidal anti-inflammatory drugs (NSAIDs)
NSAIDs are effective but should be used cautiously in older patients.[50]Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011 Apr;70(4):571-5. http://ard.bmj.com/content/70/4/571.long http://www.ncbi.nlm.nih.gov/pubmed/21257614?tool=bestpractice.com
Should be used with preventive measures, such as proton-pump inhibitors, in patients at high risk of gastrointestinal complications.[53]Freedberg DE, Kim LS, Yang YX. The Risks and benefits of ong-term use of proton pump inhibitors: expert review and best practice advice From the American Gastroenterological Association. Gastroenterology. 2017 Mar;152(4):706-15. https://www.gastrojournal.org/article/S0016-5085(17)30091-4/fulltext http://www.ncbi.nlm.nih.gov/pubmed/28257716?tool=bestpractice.com
COX-2 inhibitors may be less likely to cause gastrointestinal bleeding than traditional NSAIDs in patients with a history of gastrointestinal bleeding or comorbidities but have been associated with increased risks of cardiovascular events.[54]García Rodríguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007 Feb;132(2):498-506. https://www.gastrojournal.org/article/S0016-5085(06)02565-0/fulltext http://www.ncbi.nlm.nih.gov/pubmed/17258728?tool=bestpractice.com [55]Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. https://www.bmj.com/content/342/bmj.c7086 http://www.ncbi.nlm.nih.gov/pubmed/21224324?tool=bestpractice.com
Primary options
sulindac: 200 mg orally twice daily for 7-10 days
OR
naproxen: 500 mg orally twice daily for 10-14 days
OR
diclofenac potassium: 50 mg orally (immediate-release) two to three times daily for 10-14 days
OR
meloxicam: 7.5 to 15 mg orally once daily for 10-14 days
OR
celecoxib: 100-200 mg orally twice daily for 10-14 days
acetaminophen
Treatment recommended for SOME patients in selected patient group
Simple analgesics, such as acetaminophen, may be used for pain relief.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
colchicine
Patients with osteoarthritis-like disease or rheumatoid-like disease (i.e., where there is an inflammatory component to the arthritis) may benefit from low-dose colchicine therapy, if kidney and liver function are normal.[56]Meed SD, Spilberg I. Successful use of colchicine in acute polyarticular pseudogout. J Rheumatol. 1981 Jul-Aug;8(4):689-91. http://www.ncbi.nlm.nih.gov/pubmed/7299772?tool=bestpractice.com Evidence for colchicine use in CPPD is mostly extrapolated from evidence for the treatment of acute gout.[50]Zhang W, Doherty M, Pascual E, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011 Apr;70(4):571-5. http://ard.bmj.com/content/70/4/571.long http://www.ncbi.nlm.nih.gov/pubmed/21257614?tool=bestpractice.com
Minimum effective dose should be used because of the narrow benefit-to-risk index.[57]Neuss MN, McCallum RM, Brenckman WD, et al. Long-term colchicine administration leading to colchicine toxicity and death. Arthritis Rheum. 1986 Mar;29(3):448-9. http://www.ncbi.nlm.nih.gov/pubmed/3964322?tool=bestpractice.com
May be safer than nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with a history of gastrointestinal bleeding or comorbidities.
Colchicine may be given daily or every 3-4 days depending on the frequency of attacks.
Primary options
colchicine: 0.6 mg orally once or twice daily, maximum 1.8 mg/day
acetaminophen
Treatment recommended for SOME patients in selected patient group
Simple analgesics, such as acetaminophen, may be used for pain relief.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
systemic corticosteroids
Used when treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or colchicine has failed or is contraindicated.
Dosing regimens remain unstudied but there is little evidence that doses >20 mg/day of prednisone are warranted, and lower doses may also be effective.[58]Roane DW, Harris MD, Carpenter MT, et al. Prospective use of intramuscular triamcinolone acetonide in pseudogout. J Rheumatol. 1997 Jun;24(6):1168-70. http://www.ncbi.nlm.nih.gov/pubmed/9195527?tool=bestpractice.com
Long-term corticosteroid use can cause a variety of adverse effects. To minimize the osteoporosis that can develop, these drugs should be given with calcium and vitamin D supplements, and bone densities should be followed yearly.
Other adverse effects such as cataracts, weight gain, and type 2 diabetes mellitus are less controllable. Minimum doses should be sought and risk-to-benefit ratios weighed carefully for these drugs.
One randomized controlled trial conducted between 2018 and 2022 found that, when compared with colchicine, prednisone showed equivalent short-term efficacy for the treatment of acute CPP crystal arthritis in hospitalized patients.[59]Tristan P, Pierre R, Sébastien O, et al. Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial. The Lancet Rheumatology. 2023 Sep;5(9):e523-31. https://www.sciencedirect.com/science/article/abs/pii/S2665991323001650
Primary options
prednisone: 10-20 mg orally once daily, decrease by 5-10 mg/day every 3 days until discontinuation
acetaminophen
Treatment recommended for SOME patients in selected patient group
Simple analgesics, such as acetaminophen, may be used for pain relief.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
intra-articular corticosteroids
Used when treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or systemic corticosteroids has failed or is contraindicated.
Before injection, synovial fluid should be removed from the affected joint to minimize dilution of the drug.
Lidocaine is typically used as a local anesthetic.
Dose can be repeated every 3 months.
Primary options
dexamethasone sodium phosphate: large joints: 40-80 mg intra-articularly as a single dose; small joints: 10-20 mg intra-articularly as a single dose
OR
triamcinolone acetonide: large joints: 10-40 mg intra-articularly as a single dose; small joints: 5-10 mg intra-articularly
acetaminophen
Treatment recommended for SOME patients in selected patient group
Simple analgesics, such as acetaminophen, may be used for pain relief.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
combination of analgesics/joint aspiration/splinting
A combination of analgesics, joint aspiration, splinting, and observation may be the safest option for some patients.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
OR
tramadol: 50-100 mg orally (immediate-release) every 4-6 hours when required, maximum 400 mg/day
OR
codeine sulfate: 15-60 mg orally every 4-6 hours when required, maximum 360 mg/day
OR
oxycodone: 5-10 mg orally (immediate-release) every 4-6 hours when required; 10 mg orally (controlled-release) twice daily when required
chronic recurrent involvement of knee, hip, or shoulder joint with severe degeneration
joint replacement surgery
Patients with chronic or recurrent involvement of the knee, hip, or shoulder associated with severe joint degeneration may be good candidates for joint replacement surgery.[11]Rosenthal AK, Ryan LM. Calcium Pyrophosphate Deposition Disease. N Engl J Med. 2016 Jun 30;374(26):2575-84. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240444 http://www.ncbi.nlm.nih.gov/pubmed/27355536?tool=bestpractice.com
acetaminophen
Treatment recommended for SOME patients in selected patient group
Simple analgesics, such as acetaminophen, may be used for pain relief.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
with osteoarthritis-like disease or rheumatoid-like disease
maintenance therapy with colchicine
Patients with an inflammatory component to their disease who display a positive response to colchicine in terms of reduced severity or frequency of attacks may benefit from a low dose of colchicine to prevent further attacks.
Minimum effective dose should be used because of the narrow benefit-to-risk index.[57]Neuss MN, McCallum RM, Brenckman WD, et al. Long-term colchicine administration leading to colchicine toxicity and death. Arthritis Rheum. 1986 Mar;29(3):448-9. http://www.ncbi.nlm.nih.gov/pubmed/3964322?tool=bestpractice.com
Primary options
colchicine: 0.6 mg orally once or twice daily, maximum 1.8 mg/day
acetaminophen
Treatment recommended for SOME patients in selected patient group
Simple analgesics, such as acetaminophen, may be used for pain relief.
Primary options
acetaminophen: 325-1000 mg orally every 4-6 hours when required, maximum 4000 mg/day
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer